Cargando…

Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma

BACKGROUND: 1q21.3 amplification, which is frequently observed in metastatic melanoma, is associated with cancer progression. Interleukin enhancer‐binding factor 2 (ILF2) is located in the 1q21.3 amplified region, but its functional role or contribution to tumour aggressiveness in cutaneous melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaoqing, Bustos, Matias A., Gross, Rebecca, Ramos, Romela Irene, Takeshima, Teh‐Ling, Mills, Gordon B., Yu, Qiang, Hoon, Dave S. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516365/ https://www.ncbi.nlm.nih.gov/pubmed/34709752 http://dx.doi.org/10.1002/ctm2.608

Ejemplares similares

Acetylated DNMT1 Downregulation and Related Regulatory Factors Influence Metastatic Melanoma Patients Survival
por: Zhang, Xiaoqing, et al.
Publicado: (2021)

The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter‐tumor heterogeneity
por: Izraely, Sivan, et al.
Publicado: (2020)

Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients
por: Ramos, Romela Irene, et al.
Publicado: (2020)

Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis
por: Ramos, Romela Irene, et al.
Publicado: (2020)

Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients
por: Shoji, Yoshiaki, et al.
Publicado: (2022)

A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients
por: Bustos, Matias A., et al.
Publicado: (2020)

The Vicious Cycle of Melanoma-Microglia Crosstalk: Inter-Melanoma Variations in the Brain-Metastasis-Promoting IL-6/JAK/STAT3 Signaling Pathway
por: Izraely, Sivan, et al.
Publicado: (2023)

Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors
por: Wang, Xiaowen, et al.
Publicado: (2020)

Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients
por: Koh, Yoko, et al.
Publicado: (2022)

Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas
por: Fan, Kun, et al.
Publicado: (2017)

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications
por: Kiyohara, Eiji, et al.
Publicado: (2015)

Single-agent interleukin-2 in the treatment of metastatic melanoma
por: Petrella, T., et al.
Publicado: (2007)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)

EpiMap: Fine-tuning integrative epigenomics maps to understand complex human regulatory genomic circuitry
por: Hoon, Dave S. B., et al.
Publicado: (2021)

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer
por: Shoji, Yoshiaki, et al.
Publicado: (2022)

Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis
por: Bustos, Matias A., et al.
Publicado: (2020)

Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin
por: Yang, Junbao, et al.
Publicado: (2017)

Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser
por: Wang, Michael Z., et al.
Publicado: (2013)

RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb
por: Wang, Jinhua, et al.
Publicado: (2015)

γδ T cell activation may contribute to antitumor immunity stimulated by intralesional BCG immune therapy for cutaneous melanoma metastases
por: Ramos, Romela, et al.
Publicado: (2015)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
Publicado: (1996)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Interleukins in the treatment of melanoma
por: Xu, Xinyuan, et al.
Publicado: (2022)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
por: Leung, Anna M., et al.
Publicado: (2014)

The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
por: Pachella, Laura A., et al.
Publicado: (2015)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2023)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion
por: Fukuda, Yasunari, et al.
Publicado: (2023)

Diffuse Melanosis and Ascites due to Metastatic Malignant Melanoma
por: Sendagorta, Elena, et al.
Publicado: (2008)

Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma
por: Fukuda, Yasunari, et al.
Publicado: (2022)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Correction: Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma
por: Fukuda, Yasunari, et al.
Publicado: (2022)

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004)

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
por: Bedognetti, D, et al.
Publicado: (2013)

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
por: van de Donk, Pim P., et al.
Publicado: (2021)

Heterogeneity in the Metastatic Microenvironment: JunB-Expressing Microglia Cells as Potential Drivers of Melanoma Brain Metastasis Progression
por: Adir, Orit, et al.
Publicado: (2023)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor
por: Kobayashi, Yuta, et al.
Publicado: (2022)

Dystonia in a Patient with Melanoma Metastatic to the Brain Treated with High-Dose Interleukin-2, Radiation Therapy, and Levetiracetam
por: Sreenivasan, Varun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uueko6414gn1idgg4rc26htn26